Tirzepatide Formulation with pH and Osmolality Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing compositions of tirzepatide for treating diabetes and obesity lack acceptable stability and cause discomfort at the injection site, necessitating improved formulations that maintain stability and provide a better patient experience.

Innovation Solution

A pharmaceutical composition comprising tirzepatide with NaCl, dibasic sodium phosphate, or propylene glycol, and dibasic sodium phosphate, formulated to achieve isotonicity and pH balance, ensuring stability and reducing injection site discomfort.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing tirzepatide compositions are formulated, then the drug can be administered for treating diabetes and obesity, but the compositions lack acceptable stability and cause discomfort at the injection site

Engineering Contradiction:
ImprovestabilityVSAvoidinjection site discomfort
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by optimizing the pH range (6.0-8.0) and osmolality (200-400 mOsm/kg) of the composition, and by controlling the concentration of excipients such as dibasic sodium phosphate (0.1-10 mM), NaCl (10-150 mM), and propylene glycol (0.5-10%), thereby achieving both stability and reduced injection site discomfort

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses intermediary substances (excipients) including dibasic sodium phosphate, NaCl, and propylene glycol as mediators that facilitate the stabilization of tirzepatide and modulate the injection characteristics, thereby resolving the contradiction between stability and comfort

Inventive Principle:
Principle #24Intermediary (Mediator)

2Device complexity

If tirzepatide composition is formulated without proper excipients, then the formulation is simpler, but it lacks shelf-life stability and in-use stability

Engineering Contradiction:
Improveformulation complexityVSAvoidshelf-life stability
Core Design Contradiction:
Device complexityVSStability of the object's composition

Solution Approach 1:

The patent optimizes specific concentration parameters of excipients to achieve stability. For example, dibasic sodium phosphate is controlled at 0.1-10 mM, NaCl at 10-150 mM, and propylene glycol at 0.5-10%, which provides the necessary stability without excessive complexity

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite formulations combining tirzepatide with multiple excipients (dibasic sodium phosphate, NaCl, propylene glycol) that work synergistically to provide stability, with at least one excipient being present at optimized concentrations

Inventive Principle:
Principle #40Composite materials

3Stability of the object's composition

If tirzepatide composition is formulated with high excipient concentrations to improve stability, then shelf-life stability is enhanced, but injection site discomfort increases

Engineering Contradiction:
Improvein-use stabilityVSAvoidinjection site pain
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent carefully balances excipient concentrations within optimal ranges: dibasic sodium phosphate (0.1-10 mM), NaCl (10-150 mM), and propylene glycol (0.5-10%). These parameter optimizations ensure adequate stability while maintaining acceptable injection site comfort by avoiding excessive concentrations

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS12453756B2GIP/GLP1 agonist compositions
Publication Date: 2025.10.28 ELI LILLY & CO

AI summary

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.